SCHEMBL7228607

SCHEMBL7228607

COc1ccc2c(c1)oc1c(=O)c3cc(OC)ccc3oc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.68
▸ ALDH1A1 P00352 7/20 0.68
▸ MAPT P10636 5/20 0.68
▸ HPGD P15428 5/20 0.68
▸ NPC1 O15118 4/20 0.68
▸ RAB9A P51151 4/20 0.68
▸ SMN1; SMN2 Q16637 2/20 0.68
▸ CASP3 P42574 1/20 0.68
▸ SENP8 Q96LD8 1/20 0.68
▸ SENP7 Q9BQF6 1/20 0.68
▸ SENP6 Q9GZR1 1/20 0.68
▸ MAOA P21397 3/20 0.59
▸ POLB P06746 1/20 0.58
▸ STAT1 P42224 1/20 0.58
▸ HSD17B10 Q99714 4/20 0.53
▸ LMNA P02545 2/20 0.52
▸ CYP3A4 P08684 2/20 0.52
▸ TP53 P04637 1/20 0.52
▸ THRB P10828 1/20 0.52
▸ NFKB1 P19838 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7229420 0.94 NPC1 (0.63) KDM4EALDH1A1MAPTHPGDNPC1
SCHEMBL7234801 0.92 MAOA (0.64) KDM4EALDH1A1MAPTHPGDNPC1
SCHEMBL7227151 0.92 ALDH1A1 (0.74) KDM4EALDH1A1MAPTHPGDNPC1
SCHEMBL7227675 0.88 MAOA (0.78) KDM4EALDH1A1MAPTHPGDNPC1
SCHEMBL7236943 0.88 MAOA (0.78) KDM4EALDH1A1MAPTHPGDNPC1
SCHEMBL7331388 0.85 KDM4E (0.86) KDM4EALDH1A1MAPTHPGDNPC1
SCHEMBL2161251 0.81 ALDH1A1 (1.00) KDM4EALDH1A1MAPTHPGDNPC1
SCHEMBL29619913 0.81 ALDH1A1 (1.00) KDM4EALDH1A1MAPTHPGDNPC1
SCHEMBL7236937 0.80 MAOA (0.64) KDM4EALDH1A1MAPTHPGDNPC1
SCHEMBL7228422 0.79 MAOA (0.62) KDM4EALDH1A1MAPTHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6559177-B2 For therapy or inhibiting osteoporosis or inhibiting bone demineralization, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis in mammal WYETH 2003-05-06 — — US claimed
US-20020183310-A1 5,11-dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents WYETH 2002-12-05 — — US claimed
US-6559177-B2 For therapy or inhibiting osteoporosis or inhibiting bone demineralization, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis in mammal WYETH 2003-05-06 — — US disclosed
US-20020183310-A1 5,11-dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents WYETH 2002-12-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183310-A1 5,11-dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents ESR1, GPER1, ESR2 KDM4E 806/4885ALDH1A1 758/4885MAPT 3995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback